Takeda Pharmaceutical Co. Ltd. has bid €520m ($630m) to acquire Belgian biotech TiGenix NV, a company that is about to gain European approval of a cell-based treatment for complex perianal fistula in patients with Crohn's disease.
The acquisition fits with Takeda's previously stated plans to expand its portfolio of products in late-stage development in priority fields....








